PD-1 antibody plus chemotherapy in low PD-L1 expressing esophageal squamous cell carcinoma
1. The post-hoc analysis of JUPITER-06 showed the superiority of adding toripalimab (PD-1 antibody) to chemotherapy in patients with advanced...
1. The post-hoc analysis of JUPITER-06 showed the superiority of adding toripalimab (PD-1 antibody) to chemotherapy in patients with advanced...
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to...
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2....
1. Concurrent/adjuvant androgen-deprivation therapy has improved metastatic-free survival compared to neoadjuvant/concurrent androgen-deprivation therapy. 2. The statistical significance was mainly seen...
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months). 2....
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved...
1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6...
1. Some CHEK2 alleles were shown to have a high-risk association of breast cancer compared to other alleles that were...
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.